(PWRME, SR, BIO, CLW) Stock under Consideration by Stock-PR.com

<p align="center">Stock-PR Reporting</p>
<p align="center"><a title="Stock-PR website" href="stock-pr.com&quot; target="_blank"><img class="alignnone size-full wp-image-2414" title="stockpr_logo-site" alt="stockpr_logo-site" src="stock-pr.com/img/stockpr_logo-site.jpg&quot; /></a></p>
<p align="center"> </p>
<p align="center"><strong><a title="free stock alerts, best stock alerts, hot stock alerts, stock picks, best stock picks, free stock picks" href="pennyomega.com/?page_id=835&quot;></a></strong></p>
<p align="center"><strong><span style="COLOR: black">FREE Daily Stock Alerts From Stock-PR.com</span></strong></p>
<p style="TEXT-ALIGN: center"> </p>
<p align="center"><a title="free stock alerts, best stock alerts, hot stock alerts, stock picks, best stock picks, free stock picks" href="stock-pr.com/?page_id=1085&quot;></a></p>
<p align="center"><span style="COLOR: black"><strong><span style="COLOR: black"><strong><span style="COLOR: rgb(0,128,255)"><span style="COLOR: rgb(0,128,255)"><a title="stock-pr sign up" href="stock-pr.com/signup&quot; target="_blank"><img height="90" alt="chartstockalert" src="pennyomega.com/img/chartstockalert.jpg&quot; width="360" /></a></span></span></strong></span></strong></span></p>
<p align="center"> </p>
<p><span style="COLOR: black"><span style="COLOR: black"><span style="COLOR: rgb(0,128,255)"><span style="COLOR: rgb(0,128,255)"><font color="black"><strong><img style="WIDTH: 176px; HEIGHT: 76px" height="63" alt="power3" hspace="0" src="pennyomega.com/img/power3.png&quot; width="152" align="bottom" border="0" /> Power3 Medical Products, Inc. (PWRME.OB)<br />
<br />
Power3 Medical Products, Inc</strong>. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig's disease). Power3 Medical applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 Medical has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro®, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer's, Parkinson's, and ALS diseases, for which it is currently engaged in Phase II clinical trials. These tests are designed to analyze an individual's proteins to detect the presence of disease, a patient's disease progression, a patient's response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.<br />
<br />
The NuroPro Blood Test is Power3's medical diagnostic tool for the early detection of Neurodegenerative diseases. The analysis is designed as a tool for physicians to diagnose various degenerative diseases of the brain and nervous system. The test involves monitoring the concentration of 59 proteins in blood serum to accurately detect and distinguish between Alzheimer's disease, ALS (Lou Gehrig's disease), and Parkinson's disease. Early detection of these diseases will allow physicians to intervene at an early stage to delay disease progression, potentially allowing patients to outlive their debilitating symptoms.<br />
<br />
Parkinson's disease is a disorder of the brain that leads to shaking (tremors) and difficulty with walking, movement, and coordination. Parkinson's disease most often develops after age 50. It is one of the most common nervous system disorders of the elderly. Sometimes Parkinson's disease occurs in younger adults. It affects both men and women.</font></span></span></span></span></p>
<p><span style="COLOR: black"><span style="COLOR: black"><span style="COLOR: rgb(0,128,255)"><span style="COLOR: rgb(0,128,255)"><font color="black">Please visit Power3 Medical Products, Inc website</font> <a href="www.power3medical.com&quot;><font color="black">www.power3medical.com&lt;/font></a><font color="black">.<br />
<br />
*************************************************************************************<br />
<br />
<strong>The Standard Register Company (NYSE:SR)</strong> announced its financial results for the first quarter, which ended April 3, 2011. The Company reported revenue of $164.9 million and a net income of $0.5 million, or $0.02 per share. The results compare to revenue of $167.4 million and a net loss of $0.8 million, or $0.03 per share, last year. Revenue was down slightly relative to the prior year. Increases in core growth solutions were offset by expected declines in legacy products in every segment but Industrial. Legacy products represent the majority of the Company's portfolio and provide a foundation of stability, however the Company expects that future revenue growth will be driven by increases in core solution sales throughout all focus markets.<br />
<br />
The Standard Register Company and its subsidiaries provide business documents and related services for the healthcare, financial services, commercial, and industrial markets primarily in the United States.<br />
<br />
******************************************</font></span></span></span></span></p>
<p><span style="COLOR: black"><span style="COLOR: black"><span style="COLOR: rgb(0,128,255)"><span style="COLOR: rgb(0,128,255)"><font color="black"><strong>Bio-Rad Laboratories, Inc. (NYSE:BIO)</strong> announced financial results for the first quarter ended March 31, 2011. First-quarter reported revenues were $485.1 million, up 6.8% compared to $454.2 million reported for the first quarter of 2010. On a currency-neutral basis, quarterly revenues increased 4.9% compared to the same period last year. First-quarter gross margin was 57.2% compared to 56.6% during the same quarter last year. Net income attributable to Bio-Rad for the first quarter of 2011 was $33.0 million, or $1.16 per share on a fully diluted basis compared to $1.24 per share, during the same period last year. Earnings per share in the first quarter was negatively impacted by one-time expenses of approximately $4 million related to the retirement of debt as well as a higher effective tax rate for the quarter, primarily due to adjustments to foreign tax credits.<br />
<br />
Bio-Rad Laboratories, Inc., together with its subsidiaries, manufactures and supplies the life science research, healthcare, analytical chemistry, and other markets worldwide with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze, and purify their components.<br />
<br />
******************************************</font></span></span></span></span></p>
<p><span style="COLOR: black"><span style="COLOR: black"><span style="COLOR: rgb(0,128,255)"><span style="COLOR: rgb(0,128,255)"><font color="black"><strong>Clearwater Paper Corporation (NYSE:CLW)</strong> announced that Gordon Jones, chair, president and CEO, and Linda Massman, vice president and CFO, will be presenting at the Stephens Spring Investment Conference on Tuesday, May 24, 2011, at 8:30 AM EDT, at The New York Palace hotel in New York City. A live audio webcast of the presentation and accompanying slide materials will be accessible via Clearwater Paper's investor relations section of the company's website at</font> <a href="ir.clearwaterpaper.com/events.cfm&quot;><font color="black">ir.clearwaterpaper.com/events.cfm&lt;/font></a><font color="black">. An audio replay of the webcast will be available at the site for 90 days.<br />
<br />
Clearwater Paper Corporation manufactures and sells pulp-based products in the United States. It operates in three segments: Consumer Products, Pulp and Paperboard, and Wood Products.</font></span></span></span></span></p>
<p> </p>
<p align="center"> </p>
<p align="center">**************************************************************</p>
<p align="center"><strong>THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!</strong></p>
<p><strong><font color="blue"><font color="red">Disclaimer:</font> Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Stock-PR.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold Stock-PR.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (<font color="red">Read more at <a href="stock-pr.com/?page_id=40&quot; target="_blank"><font color="red">stock-pr.com/disclaimer&lt;/font></a></font>).</font></strong><span style="COLOR: red"><span style="COLOR: red"><strong><font color="blue">Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.</font><font color="red">Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (PWRME.OB).<br />
<br /></font></strong></span></span></p>
<p align="center">Sign Up For Free Stock Alerts At <a href="stock-pr.com/signup&quot; target="_blank">stock-pr.com/signup&lt;/a></p>
<p align="center"><a href="www.crownequityholdings.com&quot; target="_blank"><img alt="stock-pr.com/img/stock-pr_buscard.jpg&quot; src="stock-pr.com/img/stock-pr_buscard.jpg&quot; /></a></p>